

## WHO Prequalification Programme WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

### STOCRIN 50 mg film-coated tablets<sup>1</sup>

Efavirenz 50mg Tablets

STOCRIN 50 mg film-coated tablets was submitted in 2008 by Merck Sharp & Dohme B.V. to be considered for prequalification and subsequently accepted for the WHO list of prequalified products for the treatment of HIV/AIDS on 14 May 2008.

Information on the site(s) involved in the manufacture of the product and the API is available at the products listing information (<https://extranet.who.int/pqweb/medicines/ha427> )

The “Procedure for prequalification of pharmaceutical products<sup>2</sup>” defines specific evaluation mechanisms for products approved by regulatory authorities, which apply similar stringent standards for quality, safety and efficacy as those required by WHO.

The prequalification of this product by the WHO Prequalification Team: Medicines (PQTm), is based on the approval by the “European Medicines Agency” (EMA <http://www.ema.europa.eu/ema/>) in line with the “Guidelines on submission of documentation for prequalification of finished pharmaceutical products approved by stringent regulatory authorities”<sup>3</sup>.

Hence, no assessment of the data underlying this approval has been undertaken within the WHO Prequalification Programme.

However, according to the SRA guideline WHO may request additional data when considered necessary for the safe use of the product in regions relevant for prequalified products and such information may be included in the WHOPAR as a separate piece of information. In order to safeguard product quality throughout its entire intended shelf-life in hot and very humid areas, stability studies under the conditions defined for Climatic Zones IVb have been requested from the Applicant<sup>4</sup>.

Based on the submitted stability data WHO PQTm considers the following storage condition appropriate for the product when distributed in regions with zone III, IVa and IVb climatic conditions, based on available stability information:

- Do not store above 30°C.
- The shelf-life at this storage condition is 36 months.”

Based on the above, the WHOPAR for STOCRIN refers for parts 1, 3, 4, 5, 6 and 8 to the previously issued public assessment report as follows:

---

<sup>1</sup> Trade names are not prequalified by WHO. This is the national medicines regulatory authority’s responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

<sup>2</sup> [https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47\\_2](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47_2)

<sup>3</sup> [https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d\\_2](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d_2)

<sup>4</sup> [https://extranet.who.int/pqweb/sites/default/files/documents/48 Stability data SRA FPPs March2016\\_newtempl.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/48%20Stability%20data%20SRA%20FPPs%20March2016_newtempl.pdf)

WHOPAR part		Reference <sup>5</sup>
Part 1	Summary for the Public	<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000250/WC500058947.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000250/WC500058947.pdf</a>
Part 3	Package Leaflets	<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000250/WC500058946.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000250/WC500058946.pdf</a>
Part 4	Summaries Product Characteristics	<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000250/WC500058946.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000250/WC500058946.pdf</a>
Part 5	Labelling	<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000250/WC500058946.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000250/WC500058946.pdf</a>
Part 6	Discussion	<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000250/WC500058943.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000250/WC500058943.pdf</a>
Part 8	Steps taken following Authorization	<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000250/WC500058949.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000250/WC500058949.pdf</a>

Parts 2 and 7 of the WHOPAR for STOCRIN 50 mg film-coated tablets are included here.

STOCRIN 50 mg film-coated tablets contain the non-nucleoside reverse transcriptase inhibitor efavirenz.

Its WHO recommended use is for the treatment of HIV/AIDS (in combination with other antiretroviral products).

#### Summary of Prequalification Status for STOCRIN 50 mg film-coated tablets

	Initial Acceptance		Requalification	
	Date	Outcome	Date	Outcome
Status on PQ list	14 May 2008	listed	28 September 2017	listed
Dossier Evaluation	March 2008	MR	13 August 2017	requalified

PQ: prequalification

MR: meets requirements

The table represents the status of relevant completed activities only.

<sup>5</sup> <https://www.ema.europa.eu/en/medicines/human/EPAR/stocrin>